The estimated Net Worth of Patrick C. Roche is at least $56.2 mil dollars as of 10 March 2016. Dr Roche owns over 5,929 units of HTG Molecular Diagnostics Inc stock worth over $9,193 and over the last 9 years he sold HTGM stock worth over $47,004.
Dr has made over 5 trades of the HTG Molecular Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,929 units of HTGM stock worth $14,111 on 10 March 2016.
The largest trade he's ever made was buying 6,500 units of HTG Molecular Diagnostics Inc stock on 18 August 2015 worth over $37,440. On average, Dr trades about 1,491 units every 12 days since 2015. As of 10 March 2016 he still owns at least 19,152 units of HTG Molecular Diagnostics Inc stock.
You can see the complete history of Dr Roche stock trades at the bottom of the page.
Dr. Patrick C. Roche is the Sr. VP of R&D at HTG Molecular Diagnostics Inc.
Dr Roche is 68, he's been the Sr. VP of R&D of HTG Molecular Diagnostics Inc since . There are 2 older and 13 younger executives at HTG Molecular Diagnostics Inc. The oldest executive at HTG Molecular Diagnostics Inc is Harry George, 71, who is the Independent Director.
Patrick's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON, AZ, 85706.
Over the last 10 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo, eLaurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.
about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.
HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include: